/

Empresas

Vi

No verificado

Vifor International AG (CSL Vifor)

Sobre qué escribimos

BiologíaFarmacéuticaSanidad

4 Comunicados de prensa

Ver todos los comunicados de prensa

23/05/2025

Farmacéutica

Sanidad

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

Fuente

Vifor International AG (CSL Vifor)

Editor

1.00

0

29/04/2025

Farmacéutica

Sanidad

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Fuente

Vifor International AG (CSL Vifor)

Editor

1.00

0

Press Release cover image

17/10/2024

Farmacéutica

Sanidad

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Fuente

Vifor International AG (CSL Vifor)

Editor

1.00

0

Press Release cover image

24/09/2024

Farmacéutica

Sanidad

Biología

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Fuente

Vifor International AG (CSL Vifor)

Editor

1.00

0

Seguidores

0

Compatibilidad

0